Anna Mayhew

Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy

Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study

Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3

Performance of upper limb entry item to predict forced vital capacity in dysferlin-deficient limb girdle muscular dystrophy

2-year Change in Revised Hammersmith Scale scores in a large cohort of untreated paediatric type 2 and 3 SMA participants

Cardiac and pulmonary findings in dysferlinopathy: A 3‐year, longitudinal study

Water T2 could predict functional decline in patients with dysferlinopathy

Functional outcome measures in young, steroid-naïve boys with Duchenne muscular dystrophy

Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease

Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale

Consensus Guidelines for Improving Quality of Assessment and Training for Neuromuscular Diseases

Clinical Variability in Spinal Muscular Atrophy Type <scp>III</scp>

Age and baseline values predict 12 and 24-month functional changes in type 2 SMA

Performance of Upper Limb module for Duchenne muscular dystrophy

P.220The revised Hammersmith scale (RHS) for spinal muscular atrophy: longitudinal trajectories in a large international cohort of patients with type 2 and 3 SMA

Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials

Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data

Evaluator Training and Reliability for SMA Global Nusinersen Trials

Examining longitudinal functional changes in Dysferlinopathy: The JAIN Clinical Outcome Study (P5.429)

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy

Reliability of functional outcome measures in spinal muscular atrophy: Results from multi-centered, global, phase 3 clinical trials (S13.004)

Revised upper limb module for spinal muscular atrophy: Development of a new module

The Clinical Outcome Study for dysferlinopathy

Revised Hammersmith scale for spinal muscular atrophy: Longitudinal changes over six and twelve months in a large international cohort

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials

Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT)

Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients

Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy

Development of the <scp>P</scp>erformance of the <scp>U</scp>pper <scp>L</scp>imb module for <scp>D</scp>uchenne muscular dystrophy